Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
CPI-006, a B-cell activating antibody which is under development as an anticancer therapy, showed early efficacy as a potential treatment for COVID-19.
Pretreatment with G-CSF prior to receiving an autologous DC-based vaccine resulted in worse outcomes compared with no G-CSF, according to results of a phase 2b study.
Antibiotic use prior to ICI treatment may reduce ICI efficacy and result in worse survival outcomes among patients with cancer, in a retrospective study.
Neoadjuvant treatment with chemotherapy plus nivolumab resulted in a greater frequency of NSCLC downstaging compared with chemotherapy or ICI treatment alone.
A vaccine consisting of autologous dendritic cells exposed to tumor antigens was well tolerated and showed clinical benefit among patients with glioblastoma.
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
NIZ985, a heterodimer of IL-15 and IL-15α, showed antitumor activity when combined with spartalizumab among patients with pretreated, advanced solid tumors, in a phase 1 study.
NKTR-262 enhances antigen presentation and demonstrated early efficacy and a tolerable safety profile in combination with bempegaldesleukin in pretreated advanced solid tumors.
